Dosing & Uses
Dosage Forms & Strengths
capsule
- 50mg (Monodox, generic)
- 75mg (Monodox)
- 100mg (Monodox, Vibramycin, generic)
- 150mg (Adoxa)
solution, reconstituted powder for IV
- 100mg (Doxy, generic)
syrup
- 50mg/5mL (Vibramycin)
oral suspension
- 25mg/5mL (Vibramycin, generic)
tablet
- 20mg (generic)
- 50mg (Adoxa, generic)
- 75mg (Acticlate, Adoxa, generic)
- 100mg (Adoxa, generic)
- 150mg (Acticlate, generic)
tablet, delayed-release
- 50mg (Doryx)
- 60mg (Doryx MPC)
- 75mg (generic)
- 100mg (generic)
- 120mg (Doryx MPC)
- 150mg (Doryx, generic)
- 200mg (Doryx)
capsule, delayed-release
- 40mg (Oracea, generic)
periodontal extended-release liquid
- 10%
Rickettsial Infections
Indicated for Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae
Day 1: 200 mg/day PO/IV divided BID (IV may be given qDay), THEN
Maintenance: 100-200 mg/day PO/IV qDay or divided q12hr (IV may be given qDay)
Sexually Transmitted Infections
Lymphogranuloma venereum, uncomplicated urethral, endocervical or rectal infections caused by Chlamydia trachomatis
-
Uncomplicated urethral or endocervical infections
- 100 mg PO BID or 200 mg PO qDay (delayed-release) x 7 days
- For empiric therapy, give in combination with single dose of ceftriaxone if patient at high risk for gonorrhea, if follow up is a concern, or if local prevalence of gonorrhea elevated
-
Rectal infections
- Empiric therapy for acute proctitis or proctocolitis or pathogen-directed therapy for Chlamydia trachomatis (off-label): 100 mg PO BID x 7 days
- For empiric therapy, give in combination with a single dose of ceftriaxone
- Lymphogranuloma venereum: Extend duration to 21 days for presumptive therapy of lymphogranuloma venereum if patient has severe rectal symptoms (eg, bloody discharge, tenesmus, perianal ulcers or mucosal ulcers) and a positive rectal chlamydia or HIV infection
Nongonococcal urethritis caused by Ureaplasma urealyticum
- 100 mg PO BID x 7 day
Granuloma inguinale caused by Klebsiella granulomatis
- 100 mg PO BID x 3 weeks and until resolution of lesions
- Consider adding additional antibiotic if symptoms do not improve within first few days
Post-exposure prophylaxis (PEP) (Off-label)
- Postexposure prophylaxis after unprotected anal sex: 200 mg PO x 1 dose within 24-72 hr after sex among males who have sex with males and transgender women
- CDC is evaluating doxycycline post-exposure prophylaxis (doxy-PEP) to prevent gonorrhea, chlamydia, and syphilis
Syphilis caused by Treponema pallidum (when penicillin contraindicated)
- Syphilis (<1 year duration): 100 mg PO BID for 2 weeks
- Syphilis (≥1 year duration): 100 mg PO BID for 4 weeks
- Close serologic and clinical follow-up warranted as data are limited
Uncomplicated gonorrhea caused by Neisseria gonorrhoeae
- Although included in the manufacturer's prescribing information as an FDA-approved use, doxycycline is not recommended for treatment of uncomplicated gonorrhea owing to resistance
- CDC Sexually Transmitted Infections Treatment Guidelines, 2021
Respiratory Tract Infections
Indications
- Respiratory tract infections caused by Mycoplasma pneumoniae
- Psittacosis (ornithosis) caused by Chlamydophila psittaci
- Indicated for respiratory tract infections caused by the following microorganisms, when bacteriological testing indicates appropriate susceptibility to drug: Haemophilus influenzae, Klebsiella species, Streptococcus pneumoniae
Dosage
- Day 1: 200 mg/day PO/IV divided BID (IV may be given qDay), THEN
- Maintenance: 100-200 mg/day PO/IV qDay or divided q12hr PO/IV (IV may be given qDay)
Specific Bacterial Infections
Indications
- Relapsing fever due to Borrelia recurrentis
- Plague due to Yersinia pestis
- Tularemia due to Francisella tularensis
- Cholera caused by Vibrio cholerae
- Campylobacter fetus infections caused by Campylobacter fetus
- Brucellosis due to Brucella species (in conjunction with streptomycin)
- Bartonellosis due to Bartonella bacilliformis
- Gram negative microorganisms (eg, Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, urinary tract infections caused by Klebsiella species)
Dosage
- Day 1: 200 mg/day PO/IV divided BID (IV may be given qDay), THEN
- Maintenance: 100-200 mg/day PO/IV qDay or divided q12hr PO/IV (IV may be given qDay)
Ophthalmic infections
Indicated for trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence
Inclusion conjunctivitis caused by Chlamydia trachomatis
Anthrax
Indicated for anthrax due to Bacillus anthracis, including inhalational anthrax (postexposure)
100 mg PO BID for 60 days
Select Infections When Penicillin is Contraindicated
When penicillin is contraindicated, doxycycline is an alternative treatment of the following infections:
- Yaws caused by Treponema pallidum subspecies pertenue
- Vincent’s infection caused by Fusobacterium fusiforme
- Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species
Acute Intestinal Amebiasis
Indicated as adjunctive therapy for acute intestinal amebiasis
Day 1: 200 mg/day PO/IV divided BID (IV may be given qDay), THEN
Maintenance: 100-200 mg/day PO/IV qDay or divided q12hr (IV may be given qDay)
Acne Vulgaris
Indicated as adjunctive therapy for severe acne
Immediate-release: 50-100 mg PO BID or 100 mg PO qDay
Extended-release: 100 mg PO BID on day 1, then 100 mg qDay
Low-dose (subantimicrobial) dosing: 20 mg PO BID (immediate-release) or 40 mg PO qDay (delayed-release)
Rosacea
Oracea only
Indicated for treatment of only inflammatory lesions (papules and pustules) of rosacea in adults
20 mg once daily (delayed release; Oracea) or 20 mg twice daily (immediate release)
Malaria
Indicated for prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (<4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains
Prophylaxis: 100 mg PO qDay; begin taking 1-2 days before travel and continue daily during travel and for 4 weeks after traveler leaves malaria infested area
Severe infection (off-label): 100 mg PO/IV q12hr x 7 days with 3-7 days quinidine gluconate
Uncomplicated infection (off-label): 100 mg PO q12hr x 7 days with 3-7 days quinine sulfate depending on region
Equivalent dose of Doryx MPC is 120 mg
Periodontal Disease
Atridox: Apply subgingivally; dose depends on size, shape, and number of pockets treated
Dosing Considerations
Susceptible organisms
- Propionibacterium acnes, Actinomyces israelii, Acinetobacter spp, Bacillus anthracis, Bacteroides spp., Bartonella bacilliformis, Bartonella henselae, Bartonella quintana, Borrelia recurrentis, Brucella spp, Campylobacter jejuni, Chlamydia psittaci, Chlamydia trachomatis, Capnocytophaga canimorsus, Citrobacter diversus, Citrobacter freundii, Escherichia coli, Eikenella corrodens, Francisella tularensis, Haemophilus ducreyi, Helicobacter pylori, Klebsiella granulomatis, Klebsiella pneumoniae, Listeria monocytogenes, Mycoplasma hominis, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Propionibacterium acnes, Rickettsiae, Shigella spp., MRSA, Staphylococcus saprophyticus, Streptococcus spp, Treponema pallidum, Ureaplasma urealyticum, Vibrio cholerae, Yersinia enterocolitica, Yersinia pestis, VRE, mycobacteria other than tuberculosis
Dosage Forms & Strengths
capsule
- 50mg (Monodox, generic)
- 75mg (Monodox)
- 100mg (Monodox, Vibramycin, generic)
- 150mg (Adoxa)
solution, reconstituted powder for IV
- 100mg (Doxy, generic)
syrup
- 50mg/5mL (Vibramycin)
oral suspension
- 25mg/5mL (Vibramycin, generic)
tablet
- 20mg (generic)
- 50mg (Adoxa, generic)
- 75mg (Acticlate, Adoxa, generic)
- 100mg (Adoxa, generic)
- 150mg (Acticlate, generic)
tablet, delayed-release
- 50mg (Doryx)
- 60mg (Doryx MPC)
- 75mg (generic)
- 100mg (generic)
- 120mg (Doryx MPC)
- 150mg (Doryx, generic)
- 200mg (Doryx)
capsule, delayed-release
- 40mg (Oracea, generic)
General Dosing Guidelines
≤8 years: Not recommended for mild-to-moderate infections; may cause tooth discoloration and enamel hypoplasia during tooth development
>8 years, <45 Kg
- Load: 4.4 mg/kg/day PO/IV divided q12hr day 1
- Maintenance: 2.2-4.4 mg/kg/day IV/PO qDay (may divide BID for higher doses)
-
Doryx MPC
- Severe or life-threatening infections (eg, anthrax, Rocky Mountain spotted fever): 2.6 mg/kg PO BID
- Less severe infections: 5.3 mg/kg PO divided into 2 doses on day 1, then a maintenance dose of 2.6 mg/kg PO qDay
>8 years, ≥45 kg
- 100 mg PO q12hr or 50 mg PO q6hr on day 1, followed by maintenance dose of 100 mg/day as single dose or as 50 mg q12hr
- Doryx MPC: 120 mg PO q12hr on day 1, followed by maintenance dose of 120 mg/day; may increase frequency to q12hr for more severe infections, particularly chronic UTI
Anthrax
Anthrax due to Bacillus anthracis, including inhalational anthrax (postexposure)
≤8 years: 2.2 mg/kg PO/IV q12hr for 60 days (change to amoxicillin as soon as penicillin susceptibility confirmed)
>8 years
- ≤45 kg: 2.2 mg/kg PO/IV q12hr for 60 days (Doryx MPC: 2.6 mg/kg PO q12hr for 60 days)
- >45 kg: 100 mg PO/IV q12hr for 60 days (Doryx MPC: 120 mg PO q12hr for 60 days)
Malaria
Prophylaxis
- Indicated for prophylaxis of malaria due to Plasmodium falciparum in short-termtravelers (<4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxineresistant strains
- 2 mg/kg PO qDay; not to exceed 100 mg /day
- Doryx MPC: 2.4 mg/kg PO qDay
- Initiate treatment 1-2 days prior to travel to endemic area and continue for 4 weeks after leaving the area
Severe infection
- <45 kg: 2.2 mg/kg q12hr for 7 days with quinidine gluconate
- ≥45 kg (Off label): 100 mg PO/IV q12hr for 7 days with quinidine gluconate
Uncomplicated
- >8 years: 2.2 mg/kg; not to exceed 100 mg dose PO q12hr for 7 days with quinine sulfate
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (6)
- acitretin
doxycycline, acitretin. Other (see comment). Contraindicated. Comment: Both acitretin and tetracyclines can cause increased intracranial pressure.
- allogeneic cultured keratinocytes/fibroblasts in bovine collagen
doxycycline decreases effects of allogeneic cultured keratinocytes/fibroblasts in bovine collagen by Other (see comment). Contraindicated. Comment: Exposure to topical antibiotics has been shown to degrade Gintuit; if exposed, irrigate the wound thoroughly with saline and allow a suitable wash-out period to elapse before applying Gintuit.
- flibanserin
doxycycline will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of flibanserin with moderate or strong CYP3A4 inhibitors is contraindicated. Severe hypotension or syncope can occur.
- lomitapide
doxycycline increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Increases lomitapide levels several folds.
- lonafarnib
doxycycline will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is a sensitive CYP3A4 substrate. Coadministration with strong or moderate CYP3A4 inhibitors is contraindicated.
- tretinoin
doxycycline, tretinoin. Either increases toxicity of the other by unspecified interaction mechanism. Contraindicated. Both tretinoin and tetracyclines can cause increased intracranial pressure.
Serious - Use Alternative (84)
- aluminum hydroxide
aluminum hydroxide decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.
- aminolevulinic acid oral
aminolevulinic acid oral, doxycycline. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid administering other phototoxic drugs with aminolevulinic acid oral for 24 hr during perioperative period.
- aminolevulinic acid topical
doxycycline increases toxicity of aminolevulinic acid topical by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of photosensitizing drugs may enhance the phototoxic reaction to photodynamic therapy with aminolevulinic acid.
- amoxicillin
doxycycline decreases effects of amoxicillin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Tetracyclines may interfere with the bactericidal action of penicillins. Monitor for decreased therapeutic effects of penicillins if concomitantly used with a tetracycline.
- ampicillin
doxycycline decreases effects of ampicillin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Tetracyclines may interfere with the bactericidal action of penicillins. Monitor for decreased therapeutic effects of penicillins if concomitantly used with a tetracycline.
- atracurium
doxycycline increases effects of atracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
- avapritinib
doxycycline will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of avapritinib with moderate CYP3A4 inhibitors. If unable to avoid, reduce avapritinib starting dose. See drug monograph Dosage Modifications.
- axitinib
doxycycline increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid coadministration with moderate CYP3A4 inhibitors, monitor closely and reduce dose if necessary .
- BCG vaccine live
doxycycline decreases effects of BCG vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine.
- bismuth subsalicylate
bismuth subsalicylate decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- bosutinib
doxycycline increases levels of bosutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- calcium acetate
calcium acetate, doxycycline. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.
- calcium carbonate
calcium carbonate, doxycycline. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.
- calcium chloride
calcium chloride, doxycycline. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.
- calcium citrate
calcium citrate, doxycycline. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.
- calcium gluconate
calcium gluconate, doxycycline. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.
- carbonyl iron
carbonyl iron decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- cholera vaccine
doxycycline, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination.
- cisatracurium
doxycycline increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
- cobimetinib
doxycycline will increase the level or effect of cobimetinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If concurrent short term (14 days or less) use of moderate CYP3A inhibitors is unavoidable for patients who are taking cobimetinib 60 mg, reduce the cobimetinib dose to 20 mg. After discontinuation of a moderate CYP3A inhibitor, resume cobimetinib 60 mg. Use an alternative to a moderate CYP3A inhibitor in patients who are taking a reduced dose of cobimetinib (40 or 20 mg daily).
- dicloxacillin
doxycycline decreases effects of dicloxacillin by pharmacodynamic antagonism. Avoid or Use Alternate Drug.
- elacestrant
doxycycline will increase the level or effect of elacestrant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- eliglustat
doxycycline increases levels of eliglustat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Moderate CYP3A4 inhibitors are not recommended with eliglustat poor or intermediate metabolizers; reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive metabolizers .
- entrectinib
doxycycline will increase the level or effect of entrectinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of moderate CYP3A4 inhibitors with entrectinib, a CYP3A4 substrate. If coadministration unavoidable, reduce dose to 200 mg/day for patients aged 12 y or older with BSA >1.50m2. Resume previous entrectinib dose after discontinuing moderate CYP3A inhibitor for 3-5 elimination half-lives.
- fentanyl
doxycycline will increase the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4 inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.
- fentanyl intranasal
doxycycline will increase the level or effect of fentanyl intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4 inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.
- fentanyl transdermal
doxycycline will increase the level or effect of fentanyl transdermal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4 inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.
- fentanyl transmucosal
doxycycline will increase the level or effect of fentanyl transmucosal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4 inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.
- ferric maltol
ferric maltol will decrease the level or effect of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. If alternate not possible, separate administration by at least 4 hours
- ferrous fumarate
ferrous fumarate decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- ferrous gluconate
ferrous gluconate decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- ferrous sulfate
ferrous sulfate decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- infigratinib
doxycycline will increase the level or effect of infigratinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- iron dextran complex
iron dextran complex decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- iron sucrose
iron sucrose decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- isotretinoin
isotretinoin, doxycycline. Mechanism: unknown. Contraindicated. Risk of pseudotumor cerebri.
- ivabradine
doxycycline will increase the level or effect of ivabradine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of ivabradine with moderate CYP3A4 inhibitors.
- lemborexant
doxycycline will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of lemborexant with moderate or strong CYP3A inhibitors.
- lurbinectedin
doxycycline will increase the level or effect of lurbinectedin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- magnesium chloride
magnesium chloride decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- magnesium citrate
magnesium citrate decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- magnesium hydroxide
magnesium hydroxide decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- magnesium oxide
magnesium oxide decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- magnesium sulfate
magnesium sulfate decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- methoxyflurane
doxycycline, methoxyflurane. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of nephrotoxicity.
- methyl aminolevulinate
doxycycline, methyl aminolevulinate. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other.
- microbiota oral
doxycycline decreases effects of microbiota oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Microbiota oral contains bacterial spores. Antibacterial agents may decrease efficacy if coadministered. Complete antibiotic regimens 2-4 days before initiating microbiota oral. .
- midazolam intranasal
doxycycline will increase the level or effect of midazolam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of moderate CYP3A4 inhibitors with midazolam intranasal causes higher midazolam systemic exposure, which may prolong sedation.
- mobocertinib
doxycycline will increase the level or effect of mobocertinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If use of moderate CYP3A4 inhibitor unavoidable, reduce mobocertinib dose by ~50% (eg, 160 to 80 mg); closely monitor QTc interval.
- nafcillin
doxycycline decreases effects of nafcillin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. bacteriostatic antibiotics may interfere with the bactericidal actions of penicillins.
- naloxegol
doxycycline will increase the level or effect of naloxegol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministation of naloxegol with moderate CYP3A4 inhibitors is unavoidable, reduce naloxegol dose to 12.5 mg qDay
- neratinib
doxycycline will increase the level or effect of neratinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of neratinib with strong/moderate CYP3A4 inhibitors.
- olaparib
doxycycline will increase the level or effect of olaparib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A inhibitors cannot be avoided, reduce olaparib dose to 200 mg (capsule) or 150 mg (tablet) PO BID. Do not substitute tablets with capsules.
- omaveloxolone
doxycycline will increase the level or effect of omaveloxolone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unavoidable, reduce omaveloxolone dose to 100 mg/day. Closely monitor for adverse effects. If adverse effects emerge, further reduce to 50 mg/day.
- onabotulinumtoxinA
doxycycline increases effects of onabotulinumtoxinA by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
- oxacillin
doxycycline decreases effects of oxacillin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. bacteriostatic agents may inhibit the effects of bactericidal agents.
- pacritinib
doxycycline will increase the level or effect of pacritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- pancuronium
doxycycline increases effects of pancuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
- pemigatinib
doxycycline will increase the level or effect of pemigatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong or moderate CYP3A4 inhibitors is unavoidable, reduce pemigatinib dose (refer to drug monograph dosage modifications). After discontinuing the CYP3A4 inhibitor for 3 elimination half-lives, may resume previous pemigatinib dose.
- penicillin G aqueous
doxycycline decreases effects of penicillin G aqueous by pharmacodynamic antagonism. Avoid or Use Alternate Drug.
- penicillin VK
doxycycline decreases effects of penicillin VK by pharmacodynamic antagonism. Avoid or Use Alternate Drug.
- pexidartinib
doxycycline will increase the level or effect of pexidartinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong or moderate CYP3A4 inhibitors is unavoidable, reduce pexidartinib dose (refer to drug monograph dosage modifications). After discontinuing the CYP3A4 inhibitor for 3 elimination half-lives, may resume previous pexidartinib dose.
- pivmecillinam
doxycycline decreases effects of pivmecillinam by pharmacodynamic antagonism. Avoid or Use Alternate Drug.
- polysaccharide iron
polysaccharide iron decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- rapacuronium
doxycycline increases effects of rapacuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
- rocuronium
doxycycline increases effects of rocuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
- rose hips
rose hips decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- selumetinib
doxycycline will increase the level or effect of selumetinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong or moderate CYP3A4 inhibitors cannot be avoided, reduce selumetinib dosage (refer to selumetinib monograph for further information). After discontinuation of the strong or moderate CYP3A4 inhibitor for 3 elimination half-lives, resume selumetinib dose that was taken before initiating the inhibitor.
- siponimod
doxycycline will increase the level or effect of siponimod by affecting hepatic enzyme CYP2E1 metabolism. Avoid or Use Alternate Drug. Coadministration of siponimod with a moderate or strong CYP3A4 inhibitor PLUS a moderate or strong CYP2C9 inhibitor is not recommended.
- sodium bicarbonate
sodium bicarbonate decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.
- sodium citrate/citric acid
sodium citrate/citric acid decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.
- sodium sulfate/?magnesium sulfate/potassium chloride
sodium sulfate/?magnesium sulfate/potassium chloride decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Administer tetracyclines at least 2 hr before and no less than 6 hr after each dose to avoid chelation with magnesium. .
- sodium sulfate/potassium sulfate/magnesium sulfate
sodium sulfate/potassium sulfate/magnesium sulfate decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Administer tetracyclines at least 2 hr before and no less than 6 hr after each dose to avoid chelation with magnesium. .
- strontium ranelate
strontium ranelate decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Suspend strontium ranelate during antibiotic therapy.
- succinylcholine
doxycycline increases effects of succinylcholine by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
- tazemetostat
doxycycline will increase the level or effect of tazemetostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of tazemetostat with moderate CYP3A4 inhibitors. If coadministration is unavoidable, reduce tazemetostat current dose (see drug monograph Dosage Modifications).
- temocillin
doxycycline decreases effects of temocillin by pharmacodynamic antagonism. Avoid or Use Alternate Drug.
- ticarcillin
doxycycline decreases effects of ticarcillin by pharmacodynamic antagonism. Avoid or Use Alternate Drug.
- tretinoin
doxycycline, tretinoin. Either increases levels of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.
- tretinoin topical
doxycycline, tretinoin topical. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.
- tripotassium dicitratobismuthate
tripotassium dicitratobismuthate decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- typhoid vaccine live
doxycycline decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine.
- vecuronium
doxycycline increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
- venetoclax
doxycycline will increase the level or effect of venetoclax by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If a moderate CYP3A inhibitor must be used, reduce the venetoclax dose by at least 50%. Monitor more closely for signs of venetoclax toxicities.
Monitor Closely (78)
- acalabrutinib
doxycycline will increase the level or effect of acalabrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Decrease acalabrutinib dose to 100 mg once daily if coadministered with a moderate CYP3A inhibitor.
- amobarbital
amobarbital decreases levels of doxycycline by increasing metabolism. Use Caution/Monitor.
- atogepant
doxycycline will increase the level or effect of atogepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- bazedoxifene/conjugated estrogens
doxycycline will decrease the level or effect of bazedoxifene/conjugated estrogens by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- brexpiprazole
doxycycline will increase the level or effect of brexpiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Administer a quarter of brexpiprazole dose if coadministered with a moderate CYP3A4 inhibitor PLUS a strong/moderate CYP2D6 inhibitor.
- buprenorphine subdermal implant
doxycycline will increase the level or effect of buprenorphine subdermal implant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor patients already on buprenorphine subdermal implant who require newly-initiated treatment with CYP3A4 inhibitors for signs and symptoms of overmedication. If the dose of the concomitant CYP3A4 inhibitor cannot be reduced or discontinued, implant removal may be necessary and the patient should then be treated with a buprenorphine dosage form that permits dose adjustments. If a CYP3A4 inhibitor is discontinued in a patient who has been stabilized on buprenorphine, monitor the patient for withdrawal.
- buprenorphine, long-acting injection
doxycycline will increase the level or effect of buprenorphine, long-acting injection by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Patients who transfer to buprenorphine long-acting injection from transmucosal buprenorphine coadministered with CYP3A4 inhibitors should be monitored to ensure buprenorphine plasma levels are adequate. Within 2 weeks, if signs and symptoms of buprenorphine toxicity or overdose occur and the concomitant CYP3A4 inhibitor cannot be reduced or discontinued, transition the patient back to a buprenorphine formulation that permits dose adjustments.
- butabarbital
butabarbital decreases levels of doxycycline by increasing metabolism. Use Caution/Monitor.
- butalbital
butalbital decreases levels of doxycycline by increasing metabolism. Use Caution/Monitor.
- cabozantinib
doxycycline will increase the level or effect of cabozantinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- cannabidiol
doxycycline will increase the level or effect of cannabidiol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor.
- carbamazepine
carbamazepine decreases levels of doxycycline by increasing metabolism. Use Caution/Monitor.
- cefdinir
doxycycline decreases effects of cefdinir by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.
- cefditoren
doxycycline decreases effects of cefditoren by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.
- cefoxitin
doxycycline decreases effects of cefoxitin by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.
- cefpodoxime
doxycycline decreases effects of cefpodoxime by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.
- ceftriaxone
doxycycline decreases effects of ceftriaxone by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.
- cefuroxime
doxycycline decreases effects of cefuroxime by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.
- cholestyramine
cholestyramine decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
- conjugated estrogens
doxycycline will decrease the level or effect of conjugated estrogens by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- daridorexant
doxycycline will increase the level or effect of daridorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Daridorexant dose should not exceed 25 mg per night when coadministered with moderate CYP3A4 inhibitors.
- deflazacort
doxycycline will increase the level or effect of deflazacort by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Decrease deflazacort dose to one-third of the recommended dose if coadministered with moderate or strong CYP3A4 inhibitors.
- didanosine
didanosine will decrease the level or effect of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Applies to didanosine chewable tablets and powder for oral solution; administer 2 hr before or several hours after didanosine oral solution or chewable tablet administration
- digoxin
doxycycline will increase the level or effect of digoxin by altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.
- estradiol
doxycycline will decrease the level or effect of estradiol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- estrogens conjugated synthetic
doxycycline will decrease the level or effect of estrogens conjugated synthetic by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- estropipate
doxycycline will decrease the level or effect of estropipate by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- ethinylestradiol
doxycycline will decrease the level or effect of ethinylestradiol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- ferric citrate
ferric citrate will decrease the level or effect of doxycycline by drug binding in GI tract. Use Caution/Monitor. Administer doxycycline at least 1 hr before ferric citrate
- finerenone
doxycycline will increase the level or effect of finerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or moderate CYP3A4 inhibitors. Adjust finererone dosage as needed.
- guanfacine
doxycycline will increase the level or effect of guanfacine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Strong or moderate CYP3A4 inhibitors significantly increase guanfacine plasma concentrations. FDA-approved labeling for extended-release (ER) guanfacine recommends that, if coadministered, the guanfacine dosage should be decreased to half of the recommended dose. Specific recommendations for immediate-release (IR) guanfacine are not available.
- ibrutinib
doxycycline increases levels of ibrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with moderate CYP3A4 inhibitors, reduce ibrutinib dose to 280 mg qDay (B-cell malignancies) or 420 mg qDay (graft versus host disease). After CYP3A inhibitor discontinuation, resume previous dose of ibrutinib.
- ifosfamide
doxycycline will decrease the level or effect of ifosfamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use of a CYP3A4 inhibitor may decrease metabolism of ifosfamide, potentially reducing ifosfamide therapeutic effects.
- isavuconazonium sulfate
doxycycline will increase the level or effect of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- ivosidenib
doxycycline will increase the level or effect of ivosidenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with moderate CYP3A4 inhibitors may increase ivosidenib plasma concentrations, thus increasing the risk of QTc prolongation. Monitor for increased risk of QTc interval prolongation.
- lanthanum carbonate
lanthanum carbonate decreases levels of doxycycline by cation binding in GI tract. Use Caution/Monitor. Administer oral tetracycline antibiotics at least 2 hr before or after lanthanum. Interaction applies only to oral tetracyclines.
- lefamulin
doxycycline will increase the level or effect of lefamulin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for adverse effects if lefamulin is coadministered with moderate CYP3A inhibitors.
- levamlodipine
doxycycline will increase the level or effect of levamlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with moderate and strong CYP3A inhibitors results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment.
- levonorgestrel oral/ethinylestradiol/ferrous bisglycinate
doxycycline will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy.
- lumateperone
doxycycline will increase the level or effect of lumateperone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce lumateperone dose to 21 mg/day if coadministered with moderate CYP3A4 inhibitors.
- magnesium supplement
magnesium supplement will decrease the level or effect of doxycycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.
- mavacamten
doxycycline will increase the level or effect of mavacamten by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose.
- mefloquine
doxycycline will increase the level or effect of mefloquine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- mestranol
doxycycline will decrease the level or effect of mestranol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- methotrexate
doxycycline increases levels of methotrexate by decreasing elimination. Use Caution/Monitor. Tetracyclines may decrease intestinal absorption of methotrexate or interfere with the enterohepatic circulation by inhibiting bowel flora and suppressing metabolism of the drug by bacteria.
- methoxsalen
methoxsalen, doxycycline. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects.
- mipomersen
mipomersen, doxycycline. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.
- naldemedine
doxycycline increases levels of naldemedine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor naldemedine for potential adverse effects if coadministered with strong or moderate CYP3A4 inhibitors.
- oliceridine
doxycycline will increase the level or effect of oliceridine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If concomitant use is necessary, may require less frequent oliceridine dosing. Closely monitor for respiratory depression and sedation and titrate subsequent doses accordingly. If inhibitor is discontinued, consider increase oliceridine dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal.
- ospemifene
doxycycline, ospemifene. Either increases levels of the other by plasma protein binding competition. Modify Therapy/Monitor Closely.
- palbociclib
doxycycline will increase the level or effect of palbociclib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- pentobarbital
pentobarbital decreases levels of doxycycline by increasing metabolism. Use Caution/Monitor.
- phenobarbital
phenobarbital decreases levels of doxycycline by increasing metabolism. Use Caution/Monitor.
- piperacillin
doxycycline decreases effects of piperacillin by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.
- polycarbophil
polycarbophil decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
- porfimer
doxycycline, porfimer. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced photosensitivity.
- primidone
primidone decreases levels of doxycycline by increasing metabolism. Use Caution/Monitor.
- rimegepant
doxycycline will increase the level or effect of rimegepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Avoid repeating rimegepant dose within 48 hr if coadministered with a moderate CYP3A4 inhibitor.
- ruxolitinib
doxycycline will increase the level or effect of ruxolitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- ruxolitinib topical
doxycycline will increase the level or effect of ruxolitinib topical by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- secobarbital
secobarbital decreases levels of doxycycline by increasing metabolism. Use Caution/Monitor.
- sodium picosulfate/magnesium oxide/anhydrous citric acid
doxycycline decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug.
sodium picosulfate/magnesium oxide/anhydrous citric acid decreases levels of doxycycline by cation binding in GI tract. Use Caution/Monitor. Take at least 2 hours before and not less than 6 hours after administration of sodium picosulfate, magnesium oxide and anhydrous citric acid to avoid magnesium chelation. - sonidegib
doxycycline will increase the level or effect of sonidegib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Avoid coadministration of sonidegib with moderate CYP3A4 inhibitors. If a moderate CYP3A inhibitor must be used, administer the moderate CYP3A inhibitor for <14 days and monitor closely for adverse reactions, particularly musculoskeletal adverse reactions.
- sparsentan
doxycycline will increase the level or effect of sparsentan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment needed. Monitor blood pressure, serum potassium, edema, and kidney function regularly if sparsentan is coadministered with moderate CYP3A4 inhibitors.
- sucroferric oxyhydroxide
sucroferric oxyhydroxide decreases levels of doxycycline by drug binding in GI tract. Use Caution/Monitor. Do not administer at the same time; take doxycycline at least 1 hr before sucroferric oxyhydroxide.
- sufentanil SL
doxycycline will increase the level or effect of sufentanil SL by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of sufentanil SL with any CYP3A4 inhibitor may increase sufentanil plasma concentration, and, thereby increase or prolonged adverse effects, including potentially fatal respiratory depression.
- suvorexant
doxycycline will increase the level or effect of suvorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Decrease suvorexant starting dose to 5 mg HS if coadministered with moderate CYP3A4 inhibitors
- tamsulosin
doxycycline increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.
- tezacaftor
doxycycline will increase the level or effect of tezacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust tezacaftor dosage regimen if coadministered with a moderate CYP3A inhibitor.
- tinidazole
doxycycline will increase the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- tofacitinib
doxycycline increases levels of tofacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No specific dose adjustment recommended when tofacitinib coadministered with moderate CYP3A4 inhibitors; decrease tofacitinib dose if coadministered with both moderate CYP3A4 and potent CYP2C19 inhibitors.
- trabectedin
doxycycline will increase the level or effect of trabectedin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- trimagnesium citrate anhydrous
trimagnesium citrate anhydrous decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Multivalent cation-containing products may reduce bioavailability of tetracyclines; administer tetracycline at least 2 hr before or 6 hr after magnesium; use alternatives if available.
- vardenafil
doxycycline will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors
- voclosporin
doxycycline will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
- warfarin
doxycycline increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor.
- zanubrutinib
doxycycline will increase the level or effect of zanubrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce zanubrutinib (a CYP3A4 substrate) to 80 mg PO BID to when coadministered with a moderate CYP3A4 inhibitor. Interrupt dose as recommended for adverse reactions. After discontinuing the CYP3A4 inhibitor, resume previous dose of zanubrutinib.
- zinc
zinc will decrease the level or effect of doxycycline by cation binding in GI tract. Modify Therapy/Monitor Closely. Separate administration of oral tetracycline derivatives and oral zinc salts by at least 2 hr.
Minor (30)
- antithrombin alfa
doxycycline increases effects of antithrombin alfa by pharmacodynamic synergism. Minor/Significance Unknown.
- antithrombin III
doxycycline increases effects of antithrombin III by pharmacodynamic synergism. Minor/Significance Unknown.
- argatroban
doxycycline increases effects of argatroban by pharmacodynamic synergism. Minor/Significance Unknown.
- balsalazide
doxycycline will decrease the level or effect of balsalazide by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- bemiparin
doxycycline increases effects of bemiparin by pharmacodynamic synergism. Minor/Significance Unknown.
- biotin
doxycycline will decrease the level or effect of biotin by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- bivalirudin
doxycycline increases effects of bivalirudin by pharmacodynamic synergism. Minor/Significance Unknown.
- colestipol
colestipol decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- dalteparin
doxycycline increases effects of dalteparin by pharmacodynamic synergism. Minor/Significance Unknown.
- enoxaparin
doxycycline increases effects of enoxaparin by pharmacodynamic synergism. Minor/Significance Unknown.
- eslicarbazepine acetate
eslicarbazepine acetate decreases levels of doxycycline by increasing metabolism. Minor/Significance Unknown.
- estradiol vaginal
doxycycline will increase the level or effect of estradiol vaginal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- ethanol
ethanol decreases levels of doxycycline by increasing elimination. Minor/Significance Unknown.
- ethotoin
ethotoin decreases levels of doxycycline by increasing metabolism. Minor/Significance Unknown.
- fondaparinux
doxycycline increases effects of fondaparinux by pharmacodynamic synergism. Minor/Significance Unknown.
- fosphenytoin
fosphenytoin decreases levels of doxycycline by increasing metabolism. Minor/Significance Unknown.
- heparin
doxycycline increases effects of heparin by pharmacodynamic synergism. Minor/Significance Unknown.
- niacin
doxycycline will decrease the level or effect of niacin by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- oxcarbazepine
oxcarbazepine decreases levels of doxycycline by increasing metabolism. Minor/Significance Unknown.
- pantothenic acid
doxycycline will decrease the level or effect of pantothenic acid by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- phenindione
doxycycline increases effects of phenindione by pharmacodynamic synergism. Minor/Significance Unknown.
- phenytoin
phenytoin decreases levels of doxycycline by increasing metabolism. Minor/Significance Unknown.
- protamine
doxycycline increases effects of protamine by pharmacodynamic synergism. Minor/Significance Unknown.
- pyridoxine
doxycycline will decrease the level or effect of pyridoxine by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- pyridoxine (Antidote)
doxycycline will decrease the level or effect of pyridoxine (Antidote) by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- rifabutin
rifabutin decreases levels of doxycycline by increasing metabolism. Minor/Significance Unknown.
- rose hips
doxycycline decreases levels of rose hips by increasing elimination. Minor/Significance Unknown.
- sucralfate
sucralfate decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- thiamine
doxycycline will decrease the level or effect of thiamine by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- verteporfin
doxycycline, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity.
Adverse Effects
Frequency Not Defined
Anorexia
Dental discoloration
Diarrhea
Dysphagia
Enterocolitis
Erythema multiform
Esophageal ulcer
Esophagitis
Exacerbation of systemic lupus erythematosus
Exfoliative dermatitis
Glossitis
Headache
Hemolytic anemia
Hepatotoxicity
Hypoglycemia
Inflammatory anogenital lesion
Intracranial hypertension
Nausea
Neutropenia
Pericarditis
Serum sickness
Skin hyperpigmentation
Toxic epidermal necrolysis
Thrombocytopenia
Upper abdominal pain
Urticaria
Vomiting
Drug rash with eosinophilia and systemic symptoms
Postmarketing Reports
Pancreatitis
Stevens-Johnson syndrome
Maculopapular and erythematous rashes
Angioneurotic edema
Anaphylaxis
Anaphylactoid purpura
Jarisch-Herxheimer reaction in the setting of spirochete infections
Warnings
Contraindications
Documented hypersensitivity
Cautions
Use of antimicrobials#tetracyclines during tooth development (last half of pregnancy through age 8 years) can cause permanent discoloration of teeth; this adverse reaction is more common during long-term use but has been observed following repeated short-term courses; enamel hypoplasia has also been reported
Use doxycycline in pediatric patients 8 years of age or less only when potential benefits expected to outweigh risks in severe or life-threatening conditions (eg, anthrax, Rocky Mountain spotted fever); particularly when there are no alternative therapies
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis
Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking antimicrobials#tetracyclines
May result in overgrowth of non-susceptible organisms, including fungi. If such infections occur, discontinue use and institute appropriate therapy
Severe skin reactions, such as exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) reported; if severe skin reactions occur, discontinue therapy immediately and institute appropriate therapy
Intracranial hypertension (pseudotumor cerebri) reported (rare) may occur; symptoms include headache, blurred vision, diplopia, and vision loss; papilledema can be found on funduscopy; women of childbearing age who are overweight or have a history of IH are at greater risk; possibility for permanent visual loss exists; if visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted; intracranial pressure can remain elevated for weeks after drug cessation; monitor until they stabilize
All antimicrobials#tetracyclines form a stable calcium complex in any bone-forming tissue; decrease in fibula growth rate has been observed in prematures given an oral tetracycline; reaction was shown to be reversible when the drug was discontinue
Antianabolic action of the antimicrobials#tetracyclines may cause an increase in BUN; studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function
Doxycycline offers substantial but not complete suppression of the asexual blood stages of Plasmodium strains
Prescribing doxycycline in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria
In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, perform renal and hepatic studies
Drug interaction overview
- Because antimicrobials#tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage
- Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving antimicrobials#tetracyclines in conjunction with penicillin
- Absorption of antimicrobials#tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations
- Concurrent use of antimicrobials#tetracyclines, may render oral contraceptives less effective
- Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline
- Coadministration of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity
- False elevations of urinary catecholamines may occur due to interference with the fluorescence test
Pregnancy & Lactation
Pregnancy
Therapy may cause discoloration deciduous teeth, and reversible inhibition of bone growth when administered during second and third trimester of pregnancy, infancy, and childhood
All antimicrobials#tetracyclines form a stable calcium complex in any bone-forming tissue; a decrease in fibula growth rate has been observed in premature human infants given oral tetracycline in doses of 25 mg/kg every 6 hours; this reaction was shown to be reversible when drug was discontinued
Available data from published studies over decades have not shown a difference in major birth defect risk compared to unexposed pregnancies with doxycycline exposure in first trimester of pregnancy
The vast majority of reported experience during human pregnancy is short-term, first trimester exposure; there are no human data available to assess effects of long-term therapy in pregnant women such as that proposed for treatment of anthrax exposure
An expert review of published data on experiences with doxycycline use during pregnancy concluded that therapeutic doses during pregnancy are unlikely to pose substantial teratogenic risk (the quantity and quality of data were assessed as limited to fair), but the data are insufficient to state that there is no risk; there are no adequate and well-controlled studies on use of drug in pregnant women
A small prospective study of 81 pregnancies describes 43 pregnant women treated for 10 days with doxycycline during early first trimester; all mothers reported their exposed infants were normal at 1 year of age
There are no available data on risk of miscarriage following exposure to doxycycline in pregnancy; evidence of embryotoxicity also has been noted in animals treated early in pregnancy; advise patient of potential risk to fetus if drug is used during pregnancy
Based on findings from a fertility study in animals, doxycycline may impair female and male fertility; the reversibility of this finding is unclear
Lactation
Based on available published data, doxycycline is present in human milk; there are no data that inform about levels of doxycycline in breastmilk, effects on breastfed infant, or on milk production
Short-term use by lactating women not necessarily contraindicated; effects of prolonged exposure to doxycycline in breast milk are unknown; because of potential for serious adverse reactions in nursing infants from drug, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for this medication and any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Inhibits protein synthesis and, thus, bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria; may block dissociation of peptidyl t-RNA from ribosomes, causing RNA-dependent protein synthesis to arrest.
Absorption
Oral: Almost complete; reduced 20% by food or milk
Peak serum time: 1.5-4 hr
Bioavailability: Reduced at high pH
Distribution
Protein bound: 90%
Metabolism
Liver
Elimination
Half-life: 15-25 hr
Excretion: Urine (23%); feces (30%)
Administration
Oral Administration
Absorption decreased when taken with food, particularly food containing calcium
Doryx MPC, delayed-release tablet
- Do not substitute on a mg-per-mg basis with other oral doxycyclines because of differing bioavailability
- Do not chew or crush tablets
- The recommended dosage, frequency of administration, and weight-based dosage recommendations differ from that of other doxycyclines; exceed the recommended dose may increase incidence of adverse effects
- Administer with adequate amount of fluid to was down the drug and reduce risk of esophageal irritation/ulceration
-
Switching from Doryx to Doryx MPC
- Doryx MPC 60 mg replaces Doryx 50 mg
- Doryx MPC 120 mg replaces Doryx 100 mg
IV Incompatibilities
Additive: Meropenem (comp at 1 g/L mero and 200 mg/L doxy; incomp at 20 g/L and 200 mg/L doxy)
Y-site: Allopurinol, heparin, piperacillin/tazobactam
IV Compatibilities
Solution: D5W, NS
Additive: Ranitidine
Syringe: Doxapram
Y-site (partial list): Acyclovir, amiodarone, aztreonam, hydromorphone, linezolid, MgSO4, meperidine, meropenem (comp at 1 mg/mL mero and 1 mg/mL doxy; incomp at 50 mg/mL mero and 1 mg/mL doxy), morphine SO4, propofol, remifentanil
IV Preparation
For IV infusion dilute to a final concentration of 0.1-1 mg/mL w/ NS, D5W, LR, or D5/LR
IV Administration
Administer by slow IV infusion, usually over 1-2 hr
Use central line if possible
Avoid rapid administration
Other parenteral routes not recommended
Periodontal Preparation (Atridox)
If refrigerated, remove Atridox from refrigeration at least 15 minutes prior to mixing
Inject liquid contents of Syringe A (indicated by red stripe) into Syringe B (doxycycline powder) and then push the contents back into Syringe A
Complete 100 mixing cycles at a pace of 1 cycle per second using brisk strokes
Subgingival Administration (Atridox)
Does not require local anesthesia for subgingival placement
If desired, using an appropriate dental instrument, may be packed into the pocket
Dipping the edge of the instrument in water before packing will help keep Atridox from sticking to the instrument, and will help speed coagulation of Atridox
A few drops of water dripped onto the surface of Atridox once in the pocket will also aid in coagulation; if necessary, add more Atridox as described above and pack it into the pocket until the pocket is full
Storage
Tablets or capsules: Store at 20-25ºC (68-77ºF) excursions permitted to 15-30ºC (59-86ºF); protect from light and moisture; dispense in a tight, light-resistant container
Atridox: Store at 2-30ºC (36-86ºF)
Vibramycin (all formulations): Store <30ºC (86ºF) and dispensed in tight, light-resistant containers
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
doxycycline monohydrate oral - | 150 mg tablet | ![]() | |
doxycycline monohydrate oral - | 100 mg tablet | ![]() | |
doxycycline monohydrate oral - | 75 mg tablet | ![]() | |
doxycycline monohydrate oral - | 25 mg/5 mL suspension | ![]() | |
doxycycline monohydrate oral - | 50 mg capsule | ![]() | |
doxycycline monohydrate oral - | 100 mg capsule | ![]() | |
doxycycline monohydrate oral - | 150 mg tablet | ![]() | |
doxycycline monohydrate oral - | 100 mg capsule | ![]() | |
doxycycline monohydrate oral - | 75 mg capsule | ![]() | |
doxycycline monohydrate oral - | 40 mg capsule | ![]() | |
doxycycline monohydrate oral - | 50 mg capsule | ![]() | |
doxycycline monohydrate oral - | 75 mg capsule | ![]() | |
doxycycline monohydrate oral - | 50 mg tablet | ![]() | |
doxycycline monohydrate oral - | 100 mg capsule | ![]() | |
doxycycline monohydrate oral - | 100 mg capsule | ![]() | |
doxycycline monohydrate oral - | 100 mg capsule | ![]() | |
doxycycline monohydrate oral - | 100 mg tablet | ![]() | |
doxycycline monohydrate oral - | 100 mg capsule | ![]() | |
doxycycline monohydrate oral - | 75 mg tablet | ![]() | |
doxycycline monohydrate oral - | 50 mg capsule | ![]() | |
doxycycline monohydrate oral - | 100 mg tablet | ![]() | |
doxycycline monohydrate oral - | 100 mg tablet | ![]() | |
doxycycline monohydrate oral - | 150 mg capsule | ![]() | |
doxycycline monohydrate oral - | 100 mg tablet | ![]() | |
doxycycline monohydrate oral - | 100 mg capsule | ![]() | |
doxycycline monohydrate oral - | 50 mg capsule | ![]() | |
doxycycline monohydrate oral - | 150 mg capsule | ![]() | |
doxycycline monohydrate oral - | 75 mg capsule | ![]() | |
doxycycline monohydrate oral - | 25 mg/5 mL suspension | ![]() | |
doxycycline monohydrate oral - | 150 mg tablet | ![]() | |
doxycycline monohydrate oral - | 50 mg tablet | ![]() | |
doxycycline monohydrate oral - | 100 mg capsule | ![]() | |
doxycycline monohydrate oral - | 50 mg tablet | ![]() | |
doxycycline monohydrate oral - | 25 mg/5 mL suspension | ![]() | |
doxycycline monohydrate oral - | 150 mg tablet | ![]() | |
doxycycline monohydrate oral - | 75 mg tablet | ![]() | |
doxycycline monohydrate oral - | 100 mg tablet | ![]() | |
doxycycline monohydrate oral - | 100 mg tablet | ![]() | |
doxycycline monohydrate oral - | 50 mg tablet | ![]() | |
Monodox oral - | 100 mg capsule | ![]() | |
Monodox oral - | 50 mg capsule | ![]() | |
Monodox oral - | 75 mg capsule | ![]() | |
Oracea oral - | 40 mg capsule | ![]() | |
Avidoxy oral - | 100 mg tablet | ![]() |
Copyright © 2010 First DataBank, Inc.
Patient Handout
doxycycline monohydrate oral
DOXYCYCLINE 40 MG EXTENDED-RELEASE CAPSULE - ORAL
(dox-ee-SYE-kleen)
COMMON BRAND NAME(S): Oracea
USES: This medication is used to treat a certain type of skin condition called rosacea. It helps to reduce the number of pimples and bumps on the face, but it may not decrease redness. It works by reducing skin inflammation caused by rosacea.Although doxycycline belongs to the class of antibiotics known as tetracyclines, this product does not work as an antibiotic because it does not stop the growth of bacteria. Do not use this product to treat any infection, including viral infections (such as the common cold, flu). Use this medication only as prescribed by your doctor.
HOW TO USE: Read the Patient Information Leaflet if available from your pharmacist before you start using this medication and each time you get a refill. If you have any questions, ask your doctor or pharmacist.This medication is best taken by mouth on an empty stomach (at least 1 hour before or 2 hours after a meal) as directed by your doctor, usually once daily in the morning. Swallow the capsules whole. Do not crush or chew the capsules. Doing so can release all of the drug at once, increasing the risk of side effects.Take this medication with a full glass of water (8 ounces/240 milliliters) unless directed otherwise. If stomach upset occurs, taking it with food or milk may help. However, doxycycline may not work as well if you take it with food or milk (or anything high in calcium - more details below), so ask your doctor or pharmacist if you may take it that way. Do not lie down for at least 10 minutes after taking this medication.Take this medication 2 to 3 hours before or after taking any products containing aluminum, calcium, iron, magnesium, zinc or bismuth subsalicylate. Some examples include antacids, didanosine solution, quinapril, vitamins/minerals, dairy products (such as milk, yogurt), and calcium-enriched juice. These products bind with doxycycline, preventing your body from fully absorbing the drug.For the best effect, take this antibiotic at evenly spaced times. To help you remember, take it at the same time each day. Do not skip doses or take more of this medication than prescribed.Tell your doctor if your condition does not improve or if it worsens.
SIDE EFFECTS: Upset stomach, nausea, diarrhea, or mild headache may occur. If any of these effects last or get worse, notify your doctor or pharmacist promptly.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: nausea/vomiting that doesn't stop, difficult/painful swallowing, brown/gray tooth discoloration, blue/gray/brown discoloration of the skin/lips/tongue/gums, unusual tiredness, signs of kidney problems (such as change in the amount of urine), hearing changes (such as ringing in the ears, decreased hearing), severe stomach/abdominal pain.Tetracycline drugs such as doxycycline may rarely cause increased pressure around the brain (intracranial hypertension-IH). The risk of this side effect is greater for women of childbearing age who are overweight or who have had IH in the past. If IH develops, it usually goes away after doxycycline is stopped; however, there is a chance of permanent vision loss or blindness. Get medical help right away if you have: nausea/vomiting that doesn't stop, headache that is severe or doesn't go away, vision changes (such as blurred/double vision, decreased vision, sudden blindness).This medication may rarely cause a severe intestinal condition due to a bacteria called C. difficile. This condition may occur during treatment or weeks to months after treatment has stopped. Tell your doctor right away if you develop diarrhea that doesn't stop, abdominal or stomach pain/cramping, blood/mucus in your stool.If you have these symptoms, do not use anti-diarrhea or opioid products because they may make symptoms worse.Use of this medication for prolonged or repeated periods may result in oral thrush or a new vaginal yeast infection (fungal infections). Contact your doctor if you notice white patches in your mouth, a change in vaginal discharge, or other new symptoms.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: fever that doesn't go away, new or worsening lymph node swelling, rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: See also Side Effects section.Before taking doxycycline, tell your doctor or pharmacist if you are allergic to it; or to tetracycline or related drugs (such as minocycline); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney disease, liver disease, problems swallowing, esophagus problems (such as hiatal hernia, reflux disease-GERD), stomach surgery (such as gastrectomy, gastric bypass surgery), lupus.Doxycycline may cause live bacterial vaccines (such as typhoid vaccine) to not work well. Tell your health care professional that you are using doxycycline before having any immunizations/vaccinations.This medication may make you more sensitive to the sun. Limit your time in the sun. Avoid tanning booths and sunlamps. Use sunscreen and wear protective clothing when outdoors. Tell your doctor right away if you get sunburned or have skin blisters/redness.Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Children younger than 8 years may be more sensitive to the side effects of doxycycline, especially tooth discoloration. Tooth discoloration has also occurred in older children and young adults. Discuss the risks and benefits of this medication with the doctor.Tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while using doxycycline. Doxycycline may harm an unborn baby. If you become pregnant, talk to your doctor right away about the risks and benefits of this medication.This medication passes into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: See also How to Use section.Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: retinoid medications taken by mouth (such as acitretin, isotretinoin), strontium, anti-seizure medications (such as phenobarbital, phenytoin), digoxin, warfarin.This product can affect the results of certain lab tests. Make sure laboratory personnel and all your doctors know you use this drug.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: Do not share this medication with others.Lab and/or medical tests may be done while you are taking this medication. Keep all medical and lab appointments. Consult your doctor for more details.
MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Taking outdated tetracycline-related drugs can result in serious illness. Consult your pharmacist or local waste disposal company.
Information last revised May 2023. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.